Indevus Opted For Additional Sanctura QT Study Due To "Climate" At FDA
This article was originally published in Pharmaceutical Approvals Monthly
Due to "the current climate" at FDA regarding QT issues, Indevus decided to conduct an additional QT study for its incontinence agent Sanctura instead of fulfilling FDA’s requests for additional analyses of existing data, review documents show.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class